文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基因组分析鉴定出皮肤基底细胞癌的新驱动基因和进展途径。

Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.

机构信息

Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland.

Department of Dermatology, Hospital of Valais, Sierre, Switzerland.

出版信息

Nat Genet. 2016 Apr;48(4):398-406. doi: 10.1038/ng.3525. Epub 2016 Mar 7.


DOI:10.1038/ng.3525
PMID:26950094
Abstract

Basal cell carcinoma (BCC) of the skin is the most common malignant neoplasm in humans. BCC is primarily driven by the Sonic Hedgehog (Hh) pathway. However, its phenotypic variation remains unexplained. Our genetic profiling of 293 BCCs found the highest mutation rate in cancer (65 mutations/Mb). Eighty-five percent of the BCCs harbored mutations in Hh pathway genes (PTCH1, 73% or SMO, 20% (P = 6.6 × 10(-8)) and SUFU, 8%) and in TP53 (61%). However, 85% of the BCCs also harbored additional driver mutations in other cancer-related genes. We observed recurrent mutations in MYCN (30%), PPP6C (15%), STK19 (10%), LATS1 (8%), ERBB2 (4%), PIK3CA (2%), and NRAS, KRAS or HRAS (2%), and loss-of-function and deleterious missense mutations were present in PTPN14 (23%), RB1 (8%) and FBXW7 (5%). Consistent with the mutational profiles, N-Myc and Hippo-YAP pathway target genes were upregulated. Functional analysis of the mutations in MYCN, PTPN14 and LATS1 suggested their potential relevance in BCC tumorigenesis.

摘要

皮肤基底细胞癌 (BCC) 是人类最常见的恶性肿瘤。BCC 主要由 Sonic Hedgehog (Hh) 通路驱动。然而,其表型变异仍未得到解释。我们对 293 例 BCC 的基因谱分析发现,癌症的突变率最高(65 个突变/Mb)。85%的 BCC 存在 Hh 通路基因(PTCH1,73%或 SMO,20%(P = 6.6×10(-8)) 和 SUFU,8%)和 TP53(61%)的突变。然而,85%的 BCC 还存在其他癌症相关基因的额外驱动突变。我们观察到 MYCN(30%)、PPP6C(15%)、STK19(10%)、LATS1(8%)、ERBB2(4%)、PIK3CA(2%)和 NRAS、KRAS 或 HRAS(2%)的复发性突变,以及 PTPN14(23%)、RB1(8%)和 FBXW7(5%)中存在功能丧失和有害错义突变。与突变谱一致,N-Myc 和 Hippo-YAP 通路靶基因上调。对 MYCN、PTPN14 和 LATS1 突变的功能分析表明,它们可能与 BCC 肿瘤发生有关。

相似文献

[1]
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.

Nat Genet. 2016-3-7

[2]
Understanding the Molecular Genetics of Basal Cell Carcinoma.

Int J Mol Sci. 2017-11-22

[3]
Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.

Am J Clin Dermatol. 2018-4

[4]
Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma.

J Invest Dermatol. 2019-1-29

[5]
Smoothened variants explain the majority of drug resistance in basal cell carcinoma.

Cancer Cell. 2015-3-9

[6]
Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma.

Clin Cancer Res. 2022-4-1

[7]
Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas.

Br J Dermatol. 2005-1

[8]
Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.

Future Oncol. 2014-5

[9]
Molecular Variations in Histologic Subtypes of Basal Cell Carcinoma.

Skinmed. 2017-8-1

[10]
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.

Cancer Cell. 2015-3-9

引用本文的文献

[1]
A dominant SRCAP truncating mutation promotes squamous cell carcinoma progression.

Oncogenesis. 2025-8-26

[2]
Integrating 12 Spatial and Single Cell Technologies to Characterise Tumour Neighbourhoods and Cellular Interactions in three Skin Cancer Types.

bioRxiv. 2025-7-28

[3]
Ethnic-Specific and UV-Independent Mutational Signatures of Basal Cell Carcinoma in Koreans.

Int J Mol Sci. 2025-7-19

[4]
Chemoprevention of Keratinocyte Cancers: Could Aspirin Be the Solution?

J Cancer Prev. 2025-6-30

[5]
Hedgehog pathway, cell cycle, and primary cilium.

Cell Death Discov. 2025-7-3

[6]
Prevalence of genetic alterations in basal cell carcinoma patients resistant to Hedgehog pathway inhibitors: a systematic review.

Ann Med. 2025-12

[7]
Double-sided niche regulation in skin stem cell and cancer: mechanisms and clinical applications.

Mol Cancer. 2025-5-21

[8]
The implication of non-AUG-initiated N-terminally extended proteoforms in cancer.

RNA Biol. 2025-12

[9]
Basal Cell Carcinoma in Patients over 80 Years Presenting for Surgical Excision: Clinical Characteristics and Surgical Outcomes.

Curr Oncol. 2025-2-21

[10]
Basal cell carcinoma and squamous cell carcinoma of the conjunctiva in a single lesion.

Am J Ophthalmol Case Rep. 2025-3-5

本文引用的文献

[1]
The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.

Nat Genet. 2015-12

[2]
Mutations in the Kinetochore Gene KNSTRN in Basal Cell Carcinoma.

J Invest Dermatol. 2015-12

[3]
Genomic Classification of Cutaneous Melanoma.

Cell. 2015-6-18

[4]
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.

Lancet Oncol. 2015-5-13

[5]
Genome-wide analysis of human global and transcription-coupled excision repair of UV damage at single-nucleotide resolution.

Genes Dev. 2015-5-1

[6]
New basal cell carcinoma susceptibility loci.

Nat Commun. 2015-4-9

[7]
Smoothened variants explain the majority of drug resistance in basal cell carcinoma.

Cancer Cell. 2015-3-9

[8]
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.

Cancer Cell. 2015-3-9

[9]
Multiple mechanisms of MYCN dysregulation in Wilms tumour.

Oncotarget. 2015-3-30

[10]
Integrative analysis of 111 reference human epigenomes.

Nature. 2015-2-19

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索